Hear Robert A. Hauser, MD, MBA, FAAN, discuss the importance of tracking symptoms using the Parkinson’s disease diary, focusing on having patients experience a good response to medication for as much of the day as possible.
Discover how “On” and “Off” time can change over years of treatment with immediate-release; and how extended-release levodopa treatments differ from controlled-release.
Extended-release carbidopa/levodopa (ER CD/LD) can often be mistaken for controlled-release carbidopa/levodopa (CR CD/LD). Take a look at how the two differ and how ER can sustain levodopa levels for longer. Also review updated guidelines supporting the use of levodopa as first-line therapy for patients with early Parkinson’s disease and motor symptoms. See what the American Academy of Neurology now recommends for your patients with Parkinson’s.
In the past few decades, levodopa therapy has evolved to provide longer-lasting benefits for patients with Parkinson’s disease. The development of RYTARY has led to reduced “Off” time and more “On” time compared to IR CD/LD based on the ADVANCE-PD trial. In this article, Robert A. Hauser, MD, MBA, FAAN, and John C. Morgan, MD, PhD, review the results of a post hoc analysis on the duration of benefit per dose with RYTARY.
Hauser RA, et al. Jan 2021
Sign up for the Expert Institute for Parkinson’s Disease newsletter to receive production information, educational tools, resources and more!